Anti-amyloid treatments for Alzheimer's disease: A study on physicians’ perspectives DOI
Dror Shir, Tamara Shiner, Noa Bregman

et al.

Journal of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: 102(3), P. 627 - 632

Published: Oct. 29, 2024

Advances in amyloid targeting therapies (ATT) for Alzheimer's disease have introduced new options, necessitating an understanding of physicians’ perspectives as these move from trials to practice. A survey Israeli specialists found that 84% were familiar with ATT, but 60% raised doubts about their ability significantly impact progression. Neurologists more likely recommend treatments, concerns included treatment costs and limited real-world experience. The decision refer patients was influenced by patient age, financial status, diagnostic test availability. Strategies enhance physician education improve access ATT are suggested.

Language: Английский

Novel amyloid-β oligomer-targeted fluorescent probes DOI

Rikuto Kashiyama,

Hiroyuki Watanabe,

Takahiro Akasaka

et al.

Dyes and Pigments, Journal Year: 2025, Volume and Issue: unknown, P. 112680 - 112680

Published: Jan. 1, 2025

Citations

0
Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington’s disease and Prion diseases DOI

Abhiyanta Mukherjee,

Soumojit Biswas,

Ipsita Roy

et al.

Acta Pharmacologica Sinica, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Language: Английский

Citations

0
Identification of the binding site and immunoreactivity of anti-Aβ antibody 11A1: Comparison with the toxic conformation-specific TxCo-1 antibody DOI

R T Fukui,

Uswah Hafizal,

Yusuke Kageyama

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: unknown, P. 151655 - 151655

Published: March 1, 2025

Language: Английский

Citations

0
Nilotinib as a Prospective Treatment for Alzheimer’s Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis DOI Creative Commons
Ankita Srivastava,

Heather A. Renna,

Maryann Johnson

et al.

Life, Journal Year: 2024, Volume and Issue: 14(10), P. 1241 - 1241

Published: Sept. 28, 2024

Nilotinib, a tyrosine kinase inhibitor that targets the Abelson (c-Abl) signaling pathway, is FDA-approved to treat chronic myeloid leukemia. Nilotinib has properties indicative of possible utility in neuroprotection have prompted exploration repurposing drug for treatment Alzheimer's disease (AD) and Parkinson's (PD). AD progressive age-related neurodegenerative disorder characterized by deposition extracellular amyloid-β plaques intracellular neurofibrillary tangles. It incurable affects approximately 50 million patients worldwide. reduces c-Abl phosphorylation, levels, dopaminergic neuron degeneration preclinical models. This study explores effects nilotinib on amyloid processing mitochondrial functioning SH-SY5Y human neuroblastoma cell line. cells were exposed (1, 5, 10 µM). Real-time PCR immunoblot analysis performed quantify expression genes pertaining neuronal health. did not significantly change APP, BACE1, or ADAM10 mRNA levels. However, BACE1 protein was increased at 1 µM, µM without affecting APP expression. Further, affect associated with health functioning. Taken together, our findings do support efficacy neuroprotection.

Language: Английский

Citations

0
Anti-amyloid treatments for Alzheimer's disease: A study on physicians’ perspectives DOI
Dror Shir, Tamara Shiner, Noa Bregman

et al.

Journal of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: 102(3), P. 627 - 632

Published: Oct. 29, 2024

Advances in amyloid targeting therapies (ATT) for Alzheimer's disease have introduced new options, necessitating an understanding of physicians’ perspectives as these move from trials to practice. A survey Israeli specialists found that 84% were familiar with ATT, but 60% raised doubts about their ability significantly impact progression. Neurologists more likely recommend treatments, concerns included treatment costs and limited real-world experience. The decision refer patients was influenced by patient age, financial status, diagnostic test availability. Strategies enhance physician education improve access ATT are suggested.

Language: Английский

Citations

0